XML Template (2009) [5.9.2009–3:06pm] [1–12]
{TANDF_FPP}CMO/CMO_A_370883(NEW).3d (CMO) [First Proof]
Current Medical Research and Opinion
C213
Volume 25, Number 3 2008
ovarian carcinoma following the failure of second-line therapy. Gynecol Oncol 48. Verhaar-Langereis M, Karakus A, van Eijkeren M, et al. Phase II study of the
2007;104:591-5 combination of pegylated liposomal doxorubicin and topotecan in platinum-
40. Le T, Hopkins L, Baines KA, et al. Prospective evaluation of weekly topotecan resistant ovarian cancer. Int J Gynecol Cancer 2006;16:65-70
in recurrent platinum-resistant epithelial ovarian cancer. Int J Gynecol Cancer 49. Stathopoulos GP, Malamos NA, Aravantinos G, et al. Weekly administration of
2008;18:428-31 topotecan-paclitaxel as second-line treatment in ovarian cancer. Cancer
41. O’Malley DM, Azodi M, Makkenchery A, et al. Weekly topotecan in heavily Chemother Pharmacol 2007;60:123-8
pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 50. Sehouli J, Stengel D, Oskay G, et al. A phase II study of topotecan plus
2005;98:242-8 gemcitabine in the treatment of patients with relapsed ovarian cancer after
42. Sehouli J, Oskay-Oezcelik G, Stengel D, et al. Topotecan weekly versus failure of first-line chemotherapy. Ann Oncol 2002;13:1749-55
routine 5-day schedule in patients with platinum-resistant ovarian cancer 51. Chiara S, Tognoni A, Pastrone I, et al. Topotecan and ifosfamide as salvage
(TOWER): A randomized, two-stage phase-II study of the North-Eastern treatment in advanced ovarian cancer. Gynecol Oncol 2004;93:474-8
German Society of Gynaecological Oncology (NOGGO). J Clin Oncol 52. Hanjani P, Nolte S, Shahin MS. Phase II evaluation of 3-day topotecan with
2007;25(18S):Abstract 5526 cyclophosphamide in the treatment of recurrent ovarian cancer. Gynecol
43. Sehouli J, Stengel D, Oskay-Oezcelik G, et al. Nonplatinum topotecan com- Oncol 2002;85:278-84
binations versus topotecan alone for recurrent ovarian cancer: results 53. Koensgen D, Stengel D, Belau A, et al. Topotecan and carboplatin in patients
of a phase III study of the North-Eastern German Society of with platinum-sensitive recurrent ovarian cancer. Results of a multicenter
Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2008; NOGGO: phase I/II study. Cancer Chemother Pharmacol 2008;62:393-400
26:3176-82 54. Vecchione F, Fruscio R, Dell’Anna T, et al. A phase II clinical trial of topotecan
44. Scarfone G, Scambia G, Raspagliesi F, et al. A multicenter, randomized, and carboplatin in patients with newly diagnosed advanced epithelial ovarian
phase III study comparing paclitaxel/carboplatin (PC) versus topotecan/pacli- cancer. Int J Gynecol Cancer 2007;17:367-72
taxel/carboplatin (TPC) in patients with stage III (residual tumor41 cm after 55. Elkas JC, Winter 3rd WE, Chernofsky MR, et al. A phase I trial of oxaliplatin
primary surgery) and IV ovarian cancer (OC). J Clin Oncol 2006; and topotecan in recurrent ovarian carcinoma. Gynecol Oncol 2007;
24(18S):Abstract 5003 104:422-7
45. Pfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan 56. McGonigle KF, Muntz HG, Vuky JL, et al. Phase II prospective study of weekly
following carboplatin and paclitaxel in first-line treatment of advanced ovarian topotecan and bevacizumab in platinum refractory ovarian cancer or perito-
cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. neal cancer (OC). J Clin Oncol 2008;26:Abstract 5551
J Natl Cancer Inst 2006;98:1036-45 57. Schwartzberg LS, Stewart CF, Schaiquevich P, et al. Phase I dosage-finding
46. De Placido S, Scambia G, Di Vagno G, et al. Topotecan compared with no and pharmacokinetic (PK) study of intravenous topotecan and oral erlotinib in
therapy after response to surgery and carboplatin/paclitaxel in patients with patients (pts) with refractory solid tumors. J Clin Oncol 2008;20:Abstract
ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) rando- 2549
mized study. J Clin Oncol 2004;22:2635-42 58. Downs Jr LS, Judson PL, Argenta PA, et al. A prospective randomized trial of
47. Bookman MA. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel thalidomide with topotecan compared with topotecan alone in women with
(P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososo- recurrent epithelial ovarian carcinoma. Cancer 2008;112:331-9
mal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage 59. Molina JR, Kaufmann SH, Reid JM, et al. Evaluation of lapatinib and topotecan
epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J Clin Oncol combination therapy: tissue culture, murine xenograft, and phase I clinical
2006;24(18S):Abstract 5002 trial data. Clin Cancer Res 2008;14:7900-7908
12
Topotecan for relapsed ovarian cancer Sehouli & Oskay-O
¨
zcelik
www.cmrojournal.com
!
2009 Informa UK Ltd
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34